OncoCyte Corporation
OCX
$3.44
$0.051.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.49M | 115.00K | 104.00K | 176.00K | 314.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.49M | 115.00K | 104.00K | 176.00K | 314.00K |
| Cost of Revenue | 869.00K | 43.00K | 32.00K | 252.00K | 409.00K |
| Gross Profit | 617.00K | 72.00K | 72.00K | -76.00K | -95.00K |
| SG&A Expenses | 3.76M | 3.61M | 3.26M | 3.52M | 2.39M |
| Depreciation & Amortization | 22.00K | 22.00K | 22.00K | 22.00K | 22.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.91M | 6.49M | 5.77M | 5.96M | 5.37M |
| Operating Income | -5.42M | -6.38M | -5.66M | -5.79M | -5.06M |
| Income Before Tax | -33.51M | -13.49M | -4.53M | -9.13M | -15.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.51M | -13.49M | -4.53M | -9.13M | -15.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.51M | -13.49M | -4.53M | -9.13M | -15.99M |
| EBIT | -5.42M | -6.38M | -5.66M | -5.79M | -5.06M |
| EBITDA | -4.86M | -6.04M | -5.34M | -5.45M | -4.73M |
| EPS Basic | -1.93 | -0.98 | -0.36 | -1.13 | -1.96 |
| Normalized Basic EPS | -0.19 | -0.29 | -0.27 | -0.43 | -0.36 |
| EPS Diluted | -1.93 | -0.98 | -0.36 | -1.13 | -1.96 |
| Normalized Diluted EPS | -0.19 | -0.29 | -0.27 | -0.43 | -0.36 |
| Average Basic Shares Outstanding | 17.38M | 13.71M | 12.87M | 8.26M | 8.27M |
| Average Diluted Shares Outstanding | 17.38M | 13.71M | 12.87M | 8.26M | 8.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |